. . . "A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)"@en . . . . . . . "approved"@en . . . . . . . . . . . . . " "@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Undergoes biphasic elimination with an initial phase t_{1/2 α} of 3-6 hours and a terminal phase t_{1/2 β} of 5-9 hours."@en . . . . . "For the treatment of depression."@en . "LD₅₀=96mg/kg (i.v. in mice)"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "89-95% bound to plasma proteins in vitro"@en . "investigational"@en . . "Trazodonum"@en . . "2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one"@en . "# Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1365657 # Jauch R, Kopitar Z, Prox A, Zimmer A: [Pharmacokinetics and metabolism of trazodone in man (author's transl)] Arzneimittelforschung. 1976;26(11):2084-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1037253 # Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9616194 # Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15978881 # Otani K, Yasui N, Kaneko S, Ishida M, Ohkubo T, Osanai T, Sugawara K, Fukushima Y: Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7673654 # Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Gruber G, Mandl M, Strobl R, Gollner D, Prause W, Saletu B: Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):249-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11817501 # Fink HA, MacDonald R, Rutks IR, Wilt TJ: Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int. 2003 Sep;92(4):441-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12930437"@en . "Trazodone"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . " "@en . . . . . . . "Food decreases the rate and extent of absorption. "@en . . . . . "19794-93-5"@en . . . . . . . . . . . . "Trazodone binds at 5-HT2 receptor, it acts as a serotonin agonist at high doses and a serotonin antagonist at low doses. Like fluoxetine, trazodone's antidepressant activity likely results from blockage of serotonin reuptake by inhibiting serotonin reuptake pump at the presynaptic neuronal membrane. If used for long time periods, postsynaptic neuronal receptor binding sites may also be affected. The sedative effect of trazodone is likely the result of alpha-adrenergic blocking action and modest histamine blockade at H1 receptor. It weakly blocks presynaptic alpha2-adrenergic receptors and strongly inhibits postsynaptic alpha1 receptors. Trazodone does not affect the reuptake of norepinephrine or dopamine within the CNS."@en . "Trazodone"@en . "Avoid alcohol."@en . "Trazodona"@en . "Rapidly and almost completely absorbed following oral administration. Food may decrease the rate and extent of absorption. "@en . . "Humans and other mammals"@en . . . . . . . . . . . . . . . . . . . . . . . . . .